Clinical Trial Update: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Lamivudine Resistant HBeAg-Negative Chronic Hepatitis B. [Phase 4]

View source ↗

Summary

A Phase 4 study of PEGASYS (pegylated interferon alfa-2a) in lamivudine-resistant HBeAg-negative chronic hepatitis B was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hepatitis B, Chronic | Phase 4 | Status: TERMINATED